Document:

Form of Indemnification Agreement

 Exhibit 10.7 
 INDEMNIFICATION AGREEMENT 
 This Indemnification Agreement
(“Agreement”) is made as of                          , 2011 by and between Cancer Genetics, Inc., a
Delaware corporation (the “Company”), and                      (“Indemnitee”). 

RECITALS 

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors or officers or in other
capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation and
due to the fact that such exposure frequently bears no relationship to compensation paid to such officers and directors; 

WHEREAS, the Company and Indemnitee recognize that plaintiffs often seek damages in such large amounts and the costs of litigation may be
so enormous (whether or not the case is meritorious), that the defense and/or settlement of such litigation is often beyond the personal resources of directors and officers; 
 WHEREAS, the Company’s Certificate of Incorporation and Bylaws require indemnification of the officers and directors of the Company to the fullest extent permitted by the General Corporation Law of
the State of Delaware (the “DGCL”). The Bylaws expressly provide that the indemnification provisions set forth therein are not exclusive and contemplate that contracts may be entered into between the Company and its directors and officers
with respect to indemnification; 
 WHEREAS, Section 145 of the DGCL empowers the Company to indemnify its officers,
directors, employees and agents by agreement and to indemnify persons who serve, at the Company’s request, as the directors, officers, employees or agents of other corporations or enterprises; 

WHEREAS, Section 102(b)(7) of the DGCL allows the Company to include in its Certificate of Incorporation a provision limiting or
eliminating the personal liability of a director for monetary damages in respect of claims by shareholders and corporations for breach of certain fiduciary duties, and the Company has so provided in its Certificate of Incorporation that each
director shall be exculpated from such liability to the maximum extent permitted by law; 
 WHEREAS, the Company, after
reasonable investigation, has determined that the liability insurance coverage presently available to the Company may be inadequate in certain circumstances to cover all possible exposure for which Indemnitee should be protected. 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining
highly competent persons to serve as directors and officers. The Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company’s stockholders and that the

 
Company should act to assure such persons that there will be increased certainty of such protection in the future; 
 WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by
applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; 
 WHEREAS, this Agreement is a supplement to and in furtherance of the Company’s Certificate of Incorporation and Bylaws and any resolutions adopted pursuant thereto, and shall not be deemed a
substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and 
 WHEREAS, Indemnitee does not regard
the protection available under the Company’s Certificate of Incorporation, Bylaws and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company
desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified; 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and
agree as follows: 
 Section 1. Services to the Company. Indemnitee agrees to serve as a director or officer of the
Company or, at the request of the Company, as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. Indemnitee may at any time and for any reason
resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement
shall not be deemed an employment contract between the Company (or any of its subsidiaries or any other corporation, limited liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was
serving at the Company’s request as a director, officer, employee, agent or fiduciary) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee’s employment with the Company (or any of its subsidiaries or any other corporation,
limited liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving at the Company’s request as a director, officer, employee, agent or fiduciary), if any, is at will, and the
Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or any of its subsidiaries or any other corporation, limited
liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving at the Company’s request as a director, officer, employee, agent or fiduciary). The foregoing notwithstanding, this
Agreement shall continue in force after Indemnitee has ceased to serve as an officer or director of the Company. 

Section 2. Definitions. As used in this Agreement: 

  
 -2-

 (a) A “Change in Control” shall be deemed to occur upon the
earliest to occur after the date of this Agreement of any of the following events: 
 i. Acquisition of Stock
by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing thirty-five percent (35%) or more of the combined voting power of the
Company’s then outstanding securities; 
 ii. Change in Board. During any period of two
(2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered
into an agreement with the Company to effect a transaction described in Sections 2(a)(i), 2(a)(iii) or 2(a)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds
of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the
Board; 
 iii. Corporate Transactions. The effective date of a merger or consolidation of the Company with
any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being
converted into voting securities of the surviving entity) more than 51% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a
majority of the board of directors or other governing body of such surviving entity; 
 iv. Liquidation.
The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and 

v. Other Events. There occurs any other event of a nature that would be required to be reported in response to
Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.

 For purposes of this Section 2(a), the following terms shall have the following meanings: 

(A) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

(B) “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided,
however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly,

  
 -3-

 
by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. 

(C) “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided,
however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity. 

(b) “Corporate Status” describes the status of a person who is or was a director, officer, employee, agent or
fiduciary of the Company or of any other corporation, limited liability company, partnership or joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company. 

(c) “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in
respect of which indemnification is sought by Indemnitee. 
 (d) “Expenses” shall include all
reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements
or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include
(i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and
(ii) for purposes of Section 13(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise. Expenses, however, shall
not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. 

(e) “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of
corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under
this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent
Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s
rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or
relating to this Agreement or its engagement pursuant hereto. 
 (f) “Proceeding” shall include any
threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative 

  
 -4-

 
hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative legislative, or
investigative nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company,
by reason of any action taken by him or of any action on his part while acting as director or officer of the Company, or by reason of the fact that he is or was serving at the request of the Company as a director, officer, employee or agent of
another corporation, limited liability company, partnership, joint venture, trust or other enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or
advancement of expenses can be provided under this Agreement; except one initiated by an Indemnitee to enforce his rights under this Agreement. 
 Section 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made,
a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by
applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in
good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no reasonable cause to believe that his conduct was unlawful. 

Section 4. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with
the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee
shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in
good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee
shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification. 
 Section 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law
and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee
against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or
matters in such Proceeding, the Company shall indemnify 

  
 -5-

 
Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter. If the Indemnitee is not wholly
successful in such Proceeding, the Company also shall indemnify Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which the Indemnitee was successful. For
purposes of this Section and without limiting the foregoing, if any Proceeding is disposed of, on the merits or otherwise (including a disposition without prejudice), without (i) the disposition being adverse to Indemnitee, (ii) an
adjudication that Indemnitee was liable to the Company, (iii) a plea of guilty or nolo contendere by Indemnitee, (iv) an adjudication that Indemnitee did not act in good faith and in a manner Indemnitee reasonably believed to be in or not
opposed to the best interests of the Company and (v) with respect to any criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe Indemnitee’s conduct was unlawful, Indemnitee shall be considered for purposes of
this Agreement to have been successful with respect thereto. 
 Section 6. Indemnification For Expenses of a
Witness. Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise participates in any Proceeding to
which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. 
 Section 7. Additional Indemnification. 
 (a)
Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by
or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee in connection with the Proceeding. 

(b) For purposes of Section 7(a), the meaning of the phrase “to the fullest extent permitted by applicable
law” shall include, but not be limited to: 
 i. to the fullest extent permitted by the provision of the
DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and 
 ii. to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify
its officers and directors. 
 Section 8. Exclusions. Notwithstanding any provision in this Agreement, the Company
shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee: 
 (a) for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any
insurance policy or other indemnity provision; or 

  
 -6-

 (b) for any Proceedings with respect to which final judgment is rendered
against Indemnitee for payment of (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in
Section 2(a) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by
the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley
Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act), or 

(c) any Proceeding involving the enforcement of non-compete and/or non-disclosure agreements or the non-compete and/or
non-disclosure provisions of employment, consulting or similar agreements the Indemnitee may be a party to with the Company or any subsidiary of the Company or any other applicable foreign or domestic corporation, partnership, joint venture, trust
or other enterprise, if any; or 
 (d) except as provided in Section 13(d) of this Agreement, in connection
with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless
(i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

 Section 9. Advances of Expenses. The Company shall advance, to the extent not prohibited by law, the Expenses
incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within thirty (30) days after receipt by the Corporation of (i) a statement or statements from Indemnitee requesting such advance or advances from
time to time, whether prior to or after final disposition of any Proceeding, and (ii) an undertaking by or on behalf of Indemnitee to repay such amount or amounts, only if, and to the extent that, it shall ultimately be determined that
Indemnitee is not entitled to be indemnified by the Corporation as authorized by this Agreement or otherwise. Such undertaking shall be accepted without reference to the financial ability of Indemnitee to make such repayment. Advances shall be
unsecured and interest free. Advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the
advances claimed. This Section 9 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 8 or to any Proceeding for which the Company has assumed the defense thereof in accordance with
Section 10(b) of this Agreement. 
 Section 10. Procedure for Notification and Defense of Claim. 

(a) Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek
indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. 

  
 -7-

 
The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement,
Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is
entitled to indemnification following the final disposition of such action, suit or proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or
otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company shall, promptly upon receipt of such a request for
indemnification, advise the Board in writing that Indemnitee has requested indemnification. 
 (b) In the event
the Company shall be obligated to pay the Expenses of Indemnitee with respect to a Proceeding, as provided in this Agreement, the Company shall be entitled to assume the defense of such Proceeding, with counsel reasonably acceptable to Indemnitee,
upon delivery of written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any
fees of counsel subsequently incurred by Indemnitee with respect to the same Proceeding, provided that (1) Indemnitee shall have the right to employ Indemnitee’s own counsel in such Proceeding at Indemnitee’s expense and (2) if
(i) the employment of counsel by Indemnitee has been previously authorized in writing by the Company, (ii) counsel to the Company or Indemnitee shall have reasonably concluded that there may be a conflict of interest or position, or
reasonably believes that a conflict is likely to arise, on any significant issue between the Company and the Indemnitee in the conduct of such defense or (iii) the Company shall not, in fact, have employed counsel to assume the defense of such
Proceeding, then the fees and expenses of Indemnitee’s counsel shall be at the expense of the Company, except as otherwise expressly provided by this Agreement. 

(c) The Company will be entitled to participate in the Proceeding at its own expense. 

Section 11. Procedure Upon Application for Indemnification. 

(a) Upon written request by Indemnitee for indemnification pursuant to Section 10(a), a determination, if required by
applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred after the date of this Agreement, by Independent Counsel in a written opinion to the Board,
a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control shall not have occurred after the date of this Agreement, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board,
(B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors
so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Disinterested Directors, by the stockholders of the Company; and, if it is so determined that
Indemnitee is entitled to 

  
 -8-

 
indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination
with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure
and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity
making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 

(b) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to
Section 11(a) hereof, the Independent Counsel shall be selected as provided in this Section 11(b). If a Change in Control shall not have occurred after the date of this Agreement, the Independent Counsel shall be selected by the Board, and
the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred after the date of this Agreement, the Independent Counsel shall be selected by
Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel
so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written
objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this
Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and
substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty (20) days after the
submission by Indemnitee or the Company, as the case may be, of a written objection, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution
of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court
shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 11(a) hereof. Upon the due commencement of any judicial proceeding or arbitration
pursuant to Section 13(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

Section 12. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity
making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this 

  
 -9-

 
Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law,
have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or independent
legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual
determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the
applicable standard of conduct. 
 (b) Subject to Section 13(e), if the person, persons or entity empowered
or selected under Section 11 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite
determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material
fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided,
however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith
requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 12(b) shall not apply (i) if the determination of
entitlement to indemnification is to be made by the stockholders pursuant to Section 11(a) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved
to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of
stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made
thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 11(a) of this Agreement. 

(c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or
conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did
not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was
unlawful. 
 (d) Reliance as Safe Harbor. For purposes of any determination of good faith, Indemnitee
shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Company or other corporation, limited liability company, partnership, joint venture, trust employee benefit plan or other
enterprise of which Indemnitee 

  
 -10-

 
was serving as a director, officer, employee, agent or fiduciary, including financial statements, or on information supplied to Indemnitee by the officers of the Company or other corporation,
limited liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving as a director, officer, employee, agent or fiduciary in the course of their duties, or on the advice of legal
counsel for the enterprise or on information or records given or reports made to the Company or other corporation, limited liability company, partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving
as a director, officer, employee, agent or fiduciary by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Company or other corporation, limited liability company, partnership,
joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving as a director, officer, employee, agent or fiduciary. The provisions of this Section 12(d) shall not be deemed to be exclusive or to limit in any way
the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. 
 (e) Actions of Others. The knowledge and/or actions, or failure to act, of any other director, officer, agent or employee of the Company or other corporation, limited liability company,
partnership, joint venture, trust employee benefit plan or other enterprise of which Indemnitee was serving as a director, officer, employee, agent or fiduciary shall not be imputed to Indemnitee for purposes of determining the right to
indemnification under this Agreement. 
 Section 13. Remedies of Indemnitee. 

(a) Subject to Section 13(e), in the event that (i) a determination is made pursuant to Section 11 of this
Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 9 of this Agreement, (iii) no determination of entitlement to indemnification shall
have been made pursuant to Section 11(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5 or 6 or the
last sentence of Section 11(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 7 of this Agreement is not made within
ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or
unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an
adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration
Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding
pursuant to this Section 13(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section 5 of this Agreement. The Company shall not
oppose Indemnitee’s right to seek any such adjudication or award in arbitration. 

  
 -11-

 (b) In the event that a determination shall have been made pursuant to
Section 11(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 13 shall be conducted in all respects as a de novo trial, or
arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 13 the Company shall have the burden of proving Indemnitee
is not entitled to indemnification or advancement of Expenses, as the case may be. 
 (c) If a determination
shall have been made pursuant to Section 11(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this
Section 13, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or
(ii) a prohibition of such indemnification under applicable law. 
 (d) The Company shall, to the fullest
extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 13 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall
stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that the Indemnitee not be required to incur legal fees or other Expenses associated with
the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee
hereunder. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by
law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’
liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be. 

(e) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification
under this Agreement shall be required to be made prior to the final disposition of the Proceeding. 
 Section 14.
Non-exclusivity; Survival of Rights; Insurance; Subrogation. 
 (a) The rights of indemnification and to
receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company’s Certificate of Incorporation, the Company’s
By-laws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in
respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or
advancement of Expenses than would be afforded 

  
 -12-

 
currently under the Company’s Certificate of Incorporation, the Company’s By-laws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this
Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and
remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 (b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for
directors, officers, employees, or agents of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company, Indemnitee shall be covered by
such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim
pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the
respective policies. The Company and the Indemnitee shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms
of such policies. 
 (c) In the event of any payment under this Agreement, the Company shall be subrogated to the
extent of such payment to all of the rights of recovery of Indemnitee with respect to any insurance policy, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are
necessary to enable the Company to bring suit to enforce such rights. 
 (d) The Company shall not be liable
under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy,
contract, agreement or otherwise. 
 (e) The Company’s obligation to indemnify or advance Expenses hereunder
to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be
reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise. 

Section 15. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or
unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held
to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or
provisions shall be deemed reformed to the extent necessary to 

  
 -13-

 
conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without
limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent
manifested thereby. 
 Section 16. Enforcement. The Company expressly confirms and agrees that it has entered into
this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or
officer of the Company. 
 Section 17. Entire Agreement. Supersedes Prior Agreements. This Agreement constitutes the
entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided,
however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation of the Company and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

 Section 18. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding
unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 Section 19. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served
with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so
notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise except to the extent the Corporation is prejudiced in its defense of such action, suit or proceeding as a result
of such failure. 
 Section 20. Notices. All notices, requests, demands and other communications under this
Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered
mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or
(d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received: 
 (a) If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company. 

(b) If to the Company to 
 Cancer Genetics, Inc. 

                      
       

  
 -14-

                      
       
 Attention: Chairman of the Board 

or to any other address as may have been furnished to Indemnitee by the Company. 

Section 21. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this
Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be
paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to
reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers,
employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s). 
 Section 22. Applicable
Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules.
Except with respect to any arbitration commenced by Indemnitee pursuant to Section 13(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in
connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country,
(ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to
service of process in the State of Delaware, irrevocably [                    ] as its agent in the State of Delaware as such party’s
agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to
the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or
inconvenient forum. 
 Section 23. Identical Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be
produced to evidence the existence of this Agreement. 
 Section 24. Miscellaneous. Use of the masculine pronoun
shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction
thereof. 

  
 -15-

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and
year first above written. 
  

									
	CANCER GENETICS, INC.	 		 	INDEMNITEE
				
	By:	 	 	 		 	 
	Name:	 		 		 	Name:	 	
	Office:	 		 		 	Address:	 	 
		 		 		 		 	 
		 		 		 		 	 

  
 -16-Consulting Agreement between Cancer Genetics, Inc. and TSG, LLC

 Exhibit 10.8 
 CONFIDENTIAL PROPOSAL 
  

			
		
	 DATE:
	  	MAY 14, 2009
		
	 TO:
	  	DR. CHAGANTI & LOU MAIONE – CANCER GENETICS INC.
		
	 FROM:
	  	PANNA SHARMA, TSG
		
	 RE:
	  	 STRATEGIC OPPORTUNITY ROADMAP PHASE I &
 TRANSACTION ADVISORY PHASE 2

  
  

Dr. Chaganti & Mr. Maione, 

This letter can serve as a formal proposal between TSG, LLC (“TSG”) and Cancer Genetics, Inc. (the “Company”). It describes the
project streams that TSG can perform to support strategic decisions and transactions by the Company and Company Management (the “Management”). 
 Based on our conversation and visits with the company and the review of the follow up information, as well as our conversations with your group we understand that both management and investors are looking
for advice and a roadmap that can enable greater extraction of value from the company – from both the products and services business units. Both the Company and TSG believe the 14% to 16% growth per annum in the molecular diagnostics and
esoteric testing space represent significant opportunities for companies that can provide both strong, focused IP along with the service infrastructure to deliver the results of a series of valuable assays and diagnostic kits. Several of the
Company’s competencies, including sales, marketing and distribution, research and development, service operations and portfolio management need to be better brought together and integrated into a holistic growth roadmap that can deliver
meaningful returns in the next few years. 
 There are a number of central questions that need to be answered during this project – these
questions would form the basis of the roadmap and would focus on both the development of a actionable strategy for the service and product business lines: 
  

	 	1.	How should the Company’s existing assets be leveraged to drive shareholder value? 

 

	 	2.	What is the correct business model for the Company (both near- and mid-term)? 

 

	 	3.	How should the Company prioritize and value near-term business development opportunities? 

 

	 	4.	What are the financial requirements and economic return models needed to develop this strategy? 

 

	 	5.	What capabilities or organizational requirements will need to be filled in order to execute on this strategy? 

 

	 	6.	What type of partnerships, investments or alliances could bolster the Company’s capabilities and drive future growth (for both segments of the business) – and
how do they get prioritized? 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -2- 

 Figure 1 - Proposed Central Questions For Strategy Roadmap 

 

			
	 Defining the strategy map for Cancer Genetics –

Key questions to address
	  	

 

 
  

	A.	Our approach 

 TSG recommends a two
phase approach to achieving expansion and focused growth into a position of leadership in the categories of molecular testing and esoteric diagnostic services focused on cancer. We have outlined these phases below. In addition, we understand that
there are day to day needs of the business where TSG can augment existing management, and we have outlined our approach for that assignment as well. There are obvious synergies in having an onsite person during this 9 to 10 week project and those
are reflected in the pricing in Section E. 
 Phase I – Strategy Development – (Weeks 1 - 8) includes TSG’s Strategic
Roadmap Process, which addresses our key questions and results in an action plan. Figure 1 shows some central questions around the key modules in the approach that TSG uses to generate growth strategies in the life sciences. This approach considers
the following factors in select market segments: 
  

	 	•	 	 Internal capabilities examination 

  

	 	•	 	 Behavior of key buyers / buying segments 

  

	 	•	 	 Key market trends / local, regional and global 

  

	 	•	 	 Competitive dynamics / including “Coopetitive” dynamics 

 

	 	•	 	 Potential transaction opportunities / including roll-ups, and in-licensing 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -3- 

 Phase II – Strategy Execution – (Months 3-12) includes execution on the agreed upon Roadmap
for either lines of business through acquisitions, investments, capital formation, alliances or other transactions. 
 Onsite Support
– During Phase I, which is anticipated to be 8 weeks TSG will provide an onsite person from the senior team. The person will be onsite at the Rutherford, New Jersey location for 3 to 4 days per week and will participate on both the Phase I
project team as well as support day to day operational needs of the board and management. It is anticipated that the majority of time will be focused on the lab service business, and include largely the activities of:  

 

	 	•	 	 LIMS selection 

  

	 	•	 	 Operational and workflow based improvements in lab service business 

 

	 	•	 	 Solicitation and selection of partner labs where CGI can provide “overflow” support and additional capacity 

 

	 	•	 	 Improvements on management processes and reporting requirements 

 

	 	•	 	 Managing overall communications and marketing improvements needed for lab service business 

 

	B.	Team composition 

 Panna Sharma,
the Managing Partner and founder of TSG will take the lead and be responsible for the overall engagement. He will be assisted by Dr. Prashant Mehta, or Dr. James Pierce, and Laura White, or other key TSG associates in the process. We
expect to be closely involved with the company’s management, key managements and other operating personnel during the initial phase of the opinion development. 
 Completion of the first phase ranges from 7-8 weeks. The Company can at that time review to move forward with Phase 2 as outlined in this proposal. 

The project will follow the timeline below, but this timeline can be modified by mutual agreement of the parties throughout the project. Following the
mid-term deliverable TSG and The Company should have a final agreement on the required materials and efforts needed to fully develop and stress-test the ideas and play recommendations for The Company. 

 

	C.	Proposed timeline 

 The figure
below lays out an abridged timeline for completion of the project modules. For a more detailed project timeline, please see the Appendix accompanying this document. 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -4- 

 Figure 2 - Timeline, CGI Abbreviated 

 
  

	D.	Deliverables: (Weeks TBD) 

 The
major deliverable will be a presentation to the Company management team and Board of Directors and others where appropriate with an underlying fact-base. This includes: 
  

	 	1.	Executive Summary: What are the growth opportunities for the Company, from both a product and service perspective? 

 

	 	2.	Overview of the Markets and Competition: Identification of the most attractive and business models that best support the market needs identified.

  

	 	3.	Capabilities Required to Win: Why will the Company benefit from the proposed strategies, and how the Company can be re-positioned to meet these opportunities?

  

	 	4.	The Play: What mechanisms will be required so that the Company can be positioned as a leading player? What are the potential risk/reward tradeoffs for the
play(s)? 

  

	 	5.	Strategic Roadmap: How the Company can combine acquisitions and internal development to drive the success of this growth strategy? 

 

	 	6.	Go-forward Recommendations: Articulate specific acquisition or transaction goals that can be accomplished in the near term to support the R&D, validation and
implementation goals of the Strategic Roadmap. For example, this could be the roll-up of a small number of supporting satellite acquisitions for the lab service business and/or the development of a key strategic equity partner for the product
business. Describe the different categories of target companies and for each category and provide a few specific examples of companies that TSG believes are doable from a transaction perspective. 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -5- 

	E.	Consulting Project Term of Engagement and Compensation 

 TSG accepts only a limited number of transaction mandates each year and allows for extensive involvement of senior members of TSG with each mandate. Panna Sharma will be actively leading the engagement
with the Company, and he will be the primary interface to the Company’s management and Board of Directors. We view the Company Strategic Roadmap project and subsequent transaction mandate as a great fit with our core competency of integrating
strategic insights with rapid execution of an action plan grounded in transaction activity. This assignment would be of the highest priority for TSG as we believe that the Company is in an excellent position to make strategic moves that will
dramatically improve shareholder value and drive improvements to the life sciences industry. 
  

	 	•	 	 Development of the Strategic Roadmap 

  

	 	1.	This 8 week project will establish the framework for positioning the Company as a premium, scalable leader in the life sciences value chain. 

 

	 	2.	Our fee for the first phase the project is $85,000 USD (eighty five thousand USD) plus reimbursement of all TSG travel, communications and other out of pocket expenses
for the project as governed by the T&E policies of the Company. 

  

	 	3.	Payment will be due along the following schedule 

  

	 	a.	50% of the total upon contract acceptance and prior to kickoff 

  

	 	b.	25% at the midterm review 

  

	 	c.	25% at the close of Phase I and delivery of the strategic roadmap deliverable 

 

	 	4.	We expect that all T&E for Phase I will not exceed $10,000 USD, and TSG will seek specific authorization by the Company in the case that expenses beyond the $
10,000 are required for Phase I. 

  

	 	5.	In the case that the project exceeds 8 weeks due to changes in scope cause by the Company or that the Company wishes to increase the scope of analysis, presentation
refinement, develop further management alignment or review additional sub market segments, the Company will compensate TSG at the rate of $ 12,000 USD per week. 

 

	 	•	 	 On-site Support 

  

	 	1.	TSG shall offer additional support for the duration of the 8 week project, in the form of a senior member of TSG located on-site at the Company’s headquarters.

  

	 	2.	Our fee for this portion of the project is $7,000 USD per month, or an additional $1 6,000 USD (sixteen thousand USD) for the duration of Phase I.

  

	 	3.	On-site support will consist of a minimum of three, and a maximum of four days on-site per week. In addition, the TSG team member on site would also be part of the
overall project team to offset and subsidize the costs of on-site support. 

  

	 	4.	In the event that the project moves forward into Phase 2 and the Company management wishes to continue to retain a TSG team member on-site, this support service could
be extended at $21,000 USD (twenty one thousand USD) per month. 

 We are available to start between the
9th and 11th of June as per recent discussions, and we look forward to working
with you and the rest of your team on this important project. Also, I would like to note that it is our firm policy to keep such engagements highly confidential; we will not discuss contents or context of this project to anyone that is not directly
involved in this project. 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -6- 

	F.	Transaction Mandate Term of Engagement and Compensation 

 This letter can serve as a formal proposal to have TSG to act as the exclusive financial advisor to the Company with respect to potential business transactions with the Company in accordance with the
terms and conditions set forth in this document. As the Company’s exclusive financial advisor, TSG will work closely with designated Company personnel to assist the Company in executing a potential business transaction with the Company and, in
doing so, will: 
 (a) Assist the Company and the Company management in preparing information to be provided to parties that may be interested
in entering into a potential business transaction. This process may include, among other things, (i) analyzing, reviewing and refining the Company’s strategic rationale and prospects, (ii) advising and assisting the Company in writing
or strengthening its business and growth plan in the life sciences category, and (iii) helping the Company evaluate the potential returns and likelihood of success in a potential business transaction. 

(b) Develop a list of parties to be contacted regarding a potential business transaction, engage in initial discussion with such parties regarding a
potential business transaction, and assist the Company and the Stockholders in identifying the parties that are the highest priority prospective parties for a potential business transaction. 
 (c) Arrange meetings with parties acceptable to the Company and the Management that express an interest in proceeding with discussions regarding a business transaction with the Company. 

(d) Assist in coordinating due diligence efforts, structuring (including advising the Company and its Management regarding the various forms of business
transactions and assisting in the Company’s and its Management’s evaluation of potential returns and likelihood of success), documenting, and closing a potential business transaction. 

(e) Provide such other financial advisory services in connection with a potential business transaction as may be reasonably requested by the Company or
Company Management and are customary in engagements of this type. 
 For purposes of this letter, a “business transaction” or
“potential business transaction” shall mean 
 (a) any transaction or series or combination of transactions not in the ordinary course
of business of the Company in which another party directly or indirectly obtains control of the Company or its businesses]; and 
 (b) any
transaction or series or combination of transactions not in the ordinary course of business of the Company in which the Company directly or indirectly obtains control of another party or any of such other parties’ business. Such transactions
shall include, without limitation, a sale or exchange of all or substantially all of the capital stock or assets of the Company or another party; a lease of all or substantially all of the assets of the Company or another party (with or without a
purchase option); a merger or consolidation; a tender or exchange offer; a leveraged or management buy-out; the formation of a joint venture, partnership or other investment vehicle; or any transaction similar to the foregoing. 

The parties acknowledge and agree that TSG’s engagement hereunder is solely for the purposes set forth above and that nothing contained herein shall
be construed to obligate TSG to underwrite any securities 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -7- 

 
of the Company. In addition, the parties acknowledge that TSG will not provide services commonly performed by legal advisors or certified public accountants including providing tax advice,
drafting documents or preparing financial statements, all of which shall be performed by third party providers employed by the Company. 
 TSG’s Phase 2 engagement as set forth above shall commence once Phase I has been completed, expected to be on or about July 30th, 2009 and continue for a period of twelve (12) months from the date of this letter (the “Retainer
Period”). The Company agrees to pay TSG for its services during the Retainer Period a retainer fee of $10,000 USD per month for the first six months of Phase 2. Payment would begin upon initiation of Phase II of this project as authorized by
the Company in writing, the “Transaction Mandate”, plus reimbursement of all TSG travel, communications and other out of pocket expenses for the project as governed by the T&E policies of the Company. The parties agree that, if
negotiations with a party or parties interested in a potential business transaction are ongoing at the expiration of the Retainer Period, the Retainer Period automatically will be extended without any further action of the parties until such
negotiations either result in a business transaction or are terminated. 
 In the event that, at any time during the Retainer Period or the Tail
Period, which is the nine-month period following the end of the Retainer Period, the Company consummates a business transaction with any party (or an agreement or understanding is reached with respect thereto) (a) identified orally or in
writing as a prospective party to a potential business transaction by TSG during TSG’s engagement hereunder; or (b) who proposed, or to whom the Company or its Management proposed, a potential business transaction during the Retainer
Period or Tail Period the Company and agree to pay to TSG, a success or completion fee equal inline with the following parameters: 
  

	 	i.	Completion or success fee, based on the Aggregate Consideration of any Transaction. The success formulas below take into account various types of transactions, and have
defined boundaries as to the tranches, the minimum and in some cases the maximum fees payable to TSG (all figures noted below in US Dollars). 

  

	 	A.	Success Formula For Buy Side Activity: 

BUY SIDE REPRESENTATION FOR CGI (MAXIMUM FEES OF 2.6 Million USD ) 

 

							
	 Tranche
	  	 Rate
	  	 Value Range
	  	 Fee Range

	 MINIMUM
	  	Flat fee of $100,000	  	Minimum, regardless of value for up to the first three transactions	  	100,000 flat - for a maximum of 3 transactions
	 Tranche 1
	  	4.0%	  	$0.0+ Mn to 20.0 Mn USD	  	100K minimum - $800,000
	 Tranche 2
	  	3.0%	  	$20.0+ to 40.0 Mn USD	  	Up to $600,000 additional
	 Tranche 3
	  	2.0%	  	$40.0+ to maximum	  	Up to $845,000 additional

  

	 	B.	Success Formula For Sell Side Activity: 

SELL SIDE REPRESENTATION FOR CGI (NO MAXIMUM FEES) 
  

							
	 Tranche
	  	 Rate
	  	 Value Range
	  	 Fee Range

	 MINIMUM
	  	Flat fee of $400,000	  	$0 - 10.0 Mn USD	  	400,000 flat
	 Tranche 1
	  	4.0%	  	$10.0+to 25.0 Mn USD	  	400K - 1,000,000
	 Tranche 2
	  	3.0%	  	$25.0 TO 40.0 MN USD	  	Up to $450,000 additional
	 Tranche 3
	  	2.0%	  	$40.0+ to maximum	  	2% of any amount above 40.0 Mn USD

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -8- 

	 	C.	Success Formula For Corporate Development Activity: 

 CORPORATE DEVELOPMENT (NO MAXIMUM) 
  

							
	 Tranche
	  	 Rate
	  	 Value Range
	  	 Fee Details

	 Tranche 1
	  	8.0%	  	$0 – 1 Mn USD	  	This fee is payable as the Company is paid and is based on gross revenue. The fee is payable for the period of the contract with the target entity or three (3) years from the start
of the first payment – whichever is longer. In the case where there is no contract, then the payments are to be made for the three year period following the first revenue received by the Company.
	 Tranche 2
	  	6.0%	  	1.0+ Mn. USD	  	

  

	 	D.	Success Formula For Capital Raise Activity: 

 CAPITAL RAISE (NO MAXIMUM) : Capital raised from strategic industry partners or their venture units or related venture and investment funds, introduced to the Company by TSG for the purpose of
investment 
  

							
	 Tranche
	  	 Rate
	  	 Value Range
	  	 Fee Details

	 Tranche 1
	  	8.0%	  	$0 – 1 Mn USD	  	This fee is payable as the capital is received by the Company from strategic industry partners or their related venture or investment units for the purpose of investment, which such
fees payable to TSG immediately upon receipt of investment proceeds by the company.
	 Tranche 2
	  	6.0%	  	1.0+ Mn. USD	  	

 For purposes of calculating TSG’s completion fee, the term “consideration” includes the following:

 (a) the gross value of all cash, securities (debt or equity), and other property paid directly or indirectly by an acquiring entity to a
seller or sellers in connection with a business transaction; 
 (b) the aggregate principal value of all indebtedness directly or indirectly
assumed or acquired by the acquiring entity or any of its affiliates or retired, deceased or otherwise cancelled in connection with the business transaction (unless such indebtedness was included in the acquiring party’s payment to a seller or
sellers with respect to such business transaction); 
 (c) amounts paid into escrow, options or contingent payments (whether in connection with
the performance of the Company, its Management or any successor to the Company or otherwise); 
 (d) any other consideration paid to the
Company, or any other owner or partner of the Company (including payments pursuant to (i) non-compete agreements, (ii) employment or consulting agreements outside the normal business of the Company, (iii) stock options bonuses
(iv) other similar compensation 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -9- 

 
that are essentially regarded as a portion of the purchase price paid by the acquiring party, but excluding salaries or other compensation for the fair value of services to be rendered by such
shareholder, owner or partner of the Company). 
 For purposes of calculation consideration, the value of that portion of consideration
consisting of securities or other property shall be: 
  

	 	(a)	with respect to securities freely tradable in an established public market, the average closing market price on the last twenty trading days immediately prior to the
public announcement of the business transaction (or over such period as is otherwise agreed by a seller or the sellers with respect to shares to be received by them in connection with the business transaction); and 

 

	 	(b)	with respect to securities not freely tradable in an established public market and consideration consisting of other property, the fair market value of such securities
or other property as determined by the Company and TSG or, in the event the Company and TSG shall be unable to agree upon such fair market value, by an independent appraiser selected by TSG. 

 

	 	(c)	should the Company and TSG not mutually agree on the present worth of such considerations, TSG shall receive its success fee in cash as the Company receives such income
payments for the first two years starting on the day the first related product or service sale is produced as a result of the Transaction. 

 In the event that the Aggregate Consideration involved in a Transaction includes deferred or contingent payments, acquisition of additional stock or assets, or any other type of investment after the
initial closing, the Company will either 
  

	 	(a)	use their best efforts to mutually agree with TSG on their present worth which will be the value used for purposes of calculating the fee to be paid in cash at closing;

  

	 	(b)	pay TSG’s fee in cash as the Company or its stockholders receive such deferred or contingent considerations. 

In addition to the foregoing fees, the Company agrees to reimburse TSG, upon request made from time to time (but not more frequently than monthly), for
its reasonable out-of-pocket expenses as governed by the T&E policy of the Company incurred in connection with its engagement. 
 G.
Termination 
 The Company has the right to terminate this contract for any cause with 30 days notice. All notices should be communicated
in both electronic and written form to TSG Partners. The Company will not be responsible for any additional ongoing retainers or expenses related to the project from the 7 day period following notification. 

The Company has the right to terminate this contract for any cause without 30 days notice at the following points in the project: 

 

	 	1.	Following completion of the Consulting portion of the project (Phase I); and 

 

	 	2.	Following the completion of the first transaction during the Transaction Mandate (Phase 2) portion of the project. 

Upon termination TSG will prepare a summary of the work to date, provide detailed records on the contacts made, and prepare a list of contacts that will
be governed under the “tail period” of the contract. 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -10- 

 In addition the Company will be responsible for delivering to TSG all expenses incurred by TSG for the
project, and a prorated amount of the overall project and consulting fees associated with the period between last payment, and termination. 
  

	H.	Information 

 The Company and its
Management will provide to TSG all financial and other information and materials as TSG may reasonably request for purposes of its engagement hereunder. The Company and its Management understand and acknowledge that TSG will rely on the information
and material provided by the Company and its Management and such other information available from public sources as TSG may, in its sole discretion, deem prudent in performing its duties hereunder. TSG shall be entitled to rely on the accuracy and
completeness of any information or material provided by the Company and its Management without independent investigation of the accuracy of such information or material. Nothing contained in this letter shall be construed to obligate TSG to
investigate the Company, or any other owners, employees, partners or principals of the Company. 
  

	I.	Indemnification 

 The Company
agrees to indemnify and reimburse TSG and any controlling person, shareholder, affiliate, director, officer, employee or agent of TSG (collectively and individually, as the context requires, the “Agent”) against and for any losses, claims,
damages, expenses or liabilities (“Loss”) to which Agent may become subject or which Agent may suffer or incur in connection with any matter arising out of this letter, except to the extent that any such Loss is finally judicially
determined by a court of competent jurisdiction (“Determined”) to have resulted solely from Agent’s knowing breach of this letter or the gross negligence or willful misconduct of Agent in performing services which are the subject of
this letter. 
 If, in connection with the services or matters that are the subject of this letter, Agent becomes involved in any capacity in
any lawsuit, claim or other proceeding (“Action”) for which indemnity and reimbursement may be sought in accordance with this letter, the Company shall promptly reimburse Agent upon request for any and all legal or other expenses
reasonably incurred by such Agent in connection with investigating, preparing to defend or defending such Action or exercising its rights to indemnification under this letter. 
 The Company agrees that the indemnification and reimbursement commitments set forth above (a) shall apply whether or not Agent is a formal party to any such Action, and (b) are in addition to
any liability that the Company may otherwise have to Agent. 
 Agent agrees to notify the Company promptly of the assertion against it of any
claim or the commencement of any action or proceeding related to the transactions and activities contemplated this letter. Agent’s failure to so notify the Company shall not relieve the Company from any obligation or liability that it would
otherwise have except to the extent that it has been materially prejudiced by such failure. 
 The Company shall be entitled to participate in
any Action and to assume the defense thereof; provided, however, that in the event that any such Action includes both Agent and the Company, and Agent reasonably concludes that there may be legal defenses available to it that are different
from or in addition to those available to the Company, or if the Company fails to assume the defense of the Action, in either case in a timely manner, then such Agent may employ separate counsel to represent or defend it in any

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -11- 

 
such Action, and the Company will pay the reasonable fees and disbursements of such counsel; and provided, further that the Company will not be required to pay the fees and disbursements
of more than one separate counsel for all such Agents (and one separate local counsel). In any Action, the defense of which the Company assumes, the Agent will have the right to participate in such litigation and to retain its own counsel at such
Agent’s own expense. 
  

	J.	Professional Services 

 The Company
and its Management agree that competent legal counsel and certified public accountants are essential to the consummation of a business transaction. As such, the Company agrees to engage legal counsel and certified public accountants reasonably
acceptable to TSG to serve the Company in connection with a business transaction. 
  

	K.	Arbitration 

 TSG and the Company
agree to use every reasonable effort to settle any dispute or disagreement between them relative to this letter by amicable means and shall, prior to resorting to arbitration, as provided below, utilize the assistance of an independent party and
agree not to resort to further action unless and until the parties have in good faith attempted to settle such dispute or disagreement in the foregoing manner and said dispute has not been resolved within thirty (30) days after the initiation
of such attempt by either party. 
 If a good faith effort to resolve a dispute or disagreement has not produced an accord
satisfactory to both parties within such 30-day period, at the request of either party, any controversy or claim arising out of or relating to this letter, or the breach hereof, shall be settled by arbitration to be held at the office of the
American Arbitration Association (“AAA”) in New York, U. S. A. The arbitration shall be conducted in accordance with and through the United States Arbitration Act (9 U.S.C. § I et seq.) and the AAA Commercial Arbitration Rules then in
effect; provided, however, that the parties agree that any arbitration shall be conducted under AAA’s expedited procedures then in effect, regardless of the amount in controversy. Each party may be represented by counsel in such arbitration
proceeding. The Arbitration shall be conducted by one (I) arbitrator who shall be selected by the American Arbitration Association. The parties agree to request the arbitrator to render a written decision within three (3) months of the
request for arbitration or within two (2) months after appointment of the arbitrator, whichever occurs earlier. To the extent permitted under applicable law, such award shall be final and binding upon both parties. Any costs, fees or taxes
incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. Judgment upon an award rendered by the arbitrator(s) may be entered in any court of record of competent
jurisdiction in any country, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the law of such jurisdiction may require or allow. The costs and expenses of the arbitration proceedings,
including attorney’s fees, shall be borne by the losing party to the arbitration or, at the discretion of the arbitrator, may be allocated among the parties to properly reflect any partial prevailing or losing of the parties to the arbitration,
as determined by the arbitrator(s). 
  

	L.	Sole Use by Company 

 All opinions
and advice provided to the Company in connection with TSG’s engagement are intended solely for the benefit and use of the Company in connection with the matters described in this agreement, and accordingly such opinions or advice shall not be
relied upon by any person or entity other than the 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -12- 

 
Company. Neither the Company nor its Management will make any other use of any such opinions or advice. In addition, neither the Company nor any person or entity controlled by the Company will
quote or refer to TSG in any report, document, release or other communication prepared, issued or transmitted, without TSG’s prior written consent, which consent will not be unreasonably withheld. 

 

	M.	Advertisements 

 In the event of
the consummation of a business transaction with TSG’s assistance, TSG shall have the right to place advertisements in financial and other newspapers and journals at its own expense describing its services to the Company hereunder, provided that
TSG will submit a copy of any such advertisements to the Company for its approval, which approval shall not be unreasonably withheld. In addition, TSG will have rights to identify The Company as a client in its marketing materials, without
sacrificing the confidentiality of the assignment or mandate. 
  

	N.	Miscellaneous 

 This letter may not
be amended or modified except in writing signed by each of the parties hereto and shall be governed by and construed in accordance with the laws of the State of New jersey. This letter incorporates the entire understanding of the parties with
respect to the subject matter hereof and supersedes all previous agreements should they exist with respect thereto and shall be binding upon and inure to the benefit of the Company, TSG, the Agents, and their respective successors, assigns, heirs
and personal representatives. 
 If the foregoing proposal correctly sets forth our agreement and meets with your approval, we will create a
final version to be signed by both parties. 
 We look forward to working with you. If you should have any questions, please do not hesitate to
contact me. 
 Best regards, 
  

	
	/s/ Panna Sharma
	Panna Sharma

 Managing Partner & CEO, TSG 
 Mobile: +1-404-229-6955 
 Office: +1 -404-254-1660 

E-Fax: +1-212-202-4546 
 E-Mail:
panna@tsg-partners.com 
 * * * 

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -13- 

 Confirmed and accepted as of the date of this letter: 

Cancer Genetics 
  

					
	Signature:	 	/s/ Louis J. Maione
			
		 	Name:	 	Louis J. Maione
		 	Title:	 	Pres.

 APPENDIX A 
 Companies where the success, milestone or other variable payments are to be reduced 
  

					
	 	  	 Company
	  	 Reduction in Fees from Overall
Schedule

	1	  	Signature Genomics	  	33%
	2	  	Shiel Laboratories	  	33%
	3	  	Enzo Biochem	  	33%
	4	  	CBL Path	  	50%
	5	  	ABBOTT	  	50%

 Confirmed and accepted as of the date of June 12, 2009:  

Cancer Genetics 
  

					
	Signature:	 	/s/ Louis J. Maione
			
		 	Name:	 	Louis J. Maione
		 	Title:	 	Pres.

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -14- 

 TSG 
  

					
	Signature:	 	/s/ Panna Sharma
		 	Name:	 	Panna Sharma
		 	Title:	 	CEO & Managing Partner

  
  

TSG 
 1230 Peachtree St. NE, 24th Floor, Atlanta, GA 30309, USA 
 Panna Sharma, CEO & Managing Partner –
panna@tsg-partners.com 
 CONFIDENTIAL MATERIAL 
 -15-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]